Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
AstraZeneca
Medtronic
Mallinckrodt
Chubb
Julphar
Fish and Richardson
Covington
Queensland Health

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FENOFIBRATE

« Back to Dashboard

Clinical Trials for Fenofibrate

Trial ID Title Status Sponsor Phase Summary
NCT00000620 Action to Control Cardiovascular Risk in Diabetes (ACCORD) Completed Centers for Disease Control and Prevention Phase 3 The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
NCT00000620 Action to Control Cardiovascular Risk in Diabetes (ACCORD) Completed National Eye Institute (NEI) Phase 3 The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
NCT00000620 Action to Control Cardiovascular Risk in Diabetes (ACCORD) Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 3 The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
NCT00000620 Action to Control Cardiovascular Risk in Diabetes (ACCORD) Completed National Institute on Aging (NIA) Phase 3 The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
NCT00000620 Action to Control Cardiovascular Risk in Diabetes (ACCORD) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
NCT00006412 Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 The purpose of this study is to compare the safety and effectiveness of fenofibrate and pravastatin in treating HIV-positive patients who have abnormal levels of fat (lipids) in the blood. Increased lipids in the blood associated with HIV infection and anti-HIV drugs is a growing problem. The drugs used in this study are known to reduce certain lipids, but little is known about their safety and effectiveness. This study will see if one of the drugs is safer and more effective than the other, or if combining the drugs is the safest and most effective way to lower lipids. This study has been changed. On June 26, 2001, this study was reviewed by the Data and Safety Monitoring Board (DSMB). The DSMB is an independent board monitoring the progress of the study. The review showed that neither pravastatin nor fenofibrate alone were effective in reaching all the cholesterol and triglyceride goals. There were no safety concerns. It is not known if the combination of fenofibrate and pravastatin is effective and safe. Therefore, it is important to continue this study.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Fenofibrate

Condition Name

Condition Name for Fenofibrate
Intervention Trials
Dyslipidemia 23
Hypertriglyceridemia 19
Hyperlipidemia 15
Healthy 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Fenofibrate
Intervention Trials
Dyslipidemias 38
Hyperlipidemias 27
Hypertriglyceridemia 24
Diabetes Mellitus, Type 2 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Fenofibrate

Trials by Country

Trials by Country for Fenofibrate
Location Trials
United States 319
Canada 22
Germany 15
India 13
France 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Fenofibrate
Location Trials
Florida 20
California 18
Texas 17
Illinois 16
Ohio 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Fenofibrate

Clinical Trial Phase

Clinical Trial Phase for Fenofibrate
Clinical Trial Phase Trials
Phase 4 32
Phase 3 36
Phase 2/Phase 3 7
[disabled in preview] 45
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Fenofibrate
Clinical Trial Phase Trials
Completed 94
Recruiting 15
Terminated 14
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Fenofibrate

Sponsor Name

Sponsor Name for Fenofibrate
Sponsor Trials
Solvay Pharmaceuticals 17
Abbott 10
Merck Sharp & Dohme Corp. 8
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Fenofibrate
Sponsor Trials
Other 97
Industry 93
NIH 20
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
McKinsey
Citi
Boehringer Ingelheim
Daiichi Sankyo
Baxter
UBS
Colorcon
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.